Research programme: immunological therapeutics - IGM Biosciences/Sanofi
Latest Information Update: 28 Apr 2026
At a glance
- Originator IGM Biosciences; Sanofi
- Class Anti-inflammatories; Antibodies
- Mechanism of Action Immunomodulators
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Immunological disorders; Inflammation
Most Recent Events
- 28 Apr 2026 No recent reports of development identified for research development in Immunological-disorders in France (Parenteral)
- 28 Apr 2026 No recent reports of development identified for research development in Immunological-disorders in USA (Parenteral)
- 28 Apr 2026 No recent reports of development identified for research development in Inflammation in France (Parenteral)